FDA/CMS Summit
If you make FDA/CMS Summit an annual must-attend like hundreds of other pharmaceutical and biotech leaders, keep ahead of the curve and mark your calendars NOW.
Key Benefits for Attending FDA/CMS Summit:
-
Hear the critical trends and changes that affect your regulatory strategy successful strategies for dealing with FDA and CMS
-
Walk away with practical, real life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles
-
Get face-to-face access to the top regulatory thought leaders and policy makers
-
Benchmark your regulatory strategy against all the major pharmaceutical and biotech companies
Hear the Regulators’ First-Hand Perspectives on:
-
User feesdotcom/conferences/inde
-
Health care fraud prosecutions, especially in the new prescription drug benefit
-
Drug development and NDA approval strategies
-
Drug safety, risk management and post-market surveillance
-
Biogenerics/follow-on biologics
-
Personalized medicine
-
Pharma marketing and promotions regulation and enforcement
-
Marketing and promotion regulation and enforcement
-
Medicaid and Medicare reimbursement
-
Medicare Part D
-
Critical Path Initiative
-
Pricing Strategies
Last year’s FDA/CMS Summit highlighted all of the biggest names in government: Andrew von Eschenbach, Acting Commissioner, FDA, Mark McClellan, MD, CMS Administrator, Steven Galson, MD, Director, Center for Drug Evaluation and Research, FDA, and Scott Gottlieb, MD, Deputy Commissioner for Medical and Scientific Affairs, FDA.
A small sample of companies sending their teams to FDA/CMS Summit include: AstraZeneca
Bayer HealthCare Pharmaceuticals, Inc.
Boehringer Ingelheim Corp.
Bristol-Myers Squibb Company
Cephalon Inc.
Eli Lilly & Company
Genentech Inc.
GlaxoSmithKline
Hoffmann-La Roche Inc.
Johnson & Johnson
MedImmune, Inc.
Novartis
Novo Nordisk, Inc.
Pfizer
Purdue Pharma L.P.
Roche
Sanofi Aventis
Schering-Plough Corporation
Takeda Pharmaceuticals
TAP Pharmaceutical Products Inc.
UCB Pharma
Wyeth
